Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Oliver B. Pepper"'
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Background Children with Down syndrome (DS) have increased risk for developing AML (DS-AMKL), and they usually experience severe therapy-related toxicities compared to non DS-AMKL. Refractory/relapsed disease has very poor outcome, and patients would
Autor:
David O. Azorsa, Justin J. Montoya, Daniel H. Wai, Robert J. Arceci, David W. Lee, Oliver B. Pepper, Peter Azorsa
Publikováno v:
Cancer Research. 77:3338-3338
Ewing sarcoma is the second most common cancer of bone and soft tissue arising in children and young adults. Although the survival rate has improved for patients treated for localized disease, the survival rate for patients with metastatic tumor rema
Publikováno v:
Cancer Research. 76:B02-B02
Background: Acute myeloid leukemia (AML) continues to have an overall poor prognosis of about 50% in children. Treatment options for relapsed or refractory AML are limited. Bortezomib, a well-established proteasome inhibitor, is used in AML therapy.
Autor:
David O. Azorsa, Robert J. Arceci, David W. Lee, Oliver B. Pepper, Ratan D. Bhardwaj, Madhavi Chakravadhanula, Justin J. Montoya, Victor V. Ozols
Publikováno v:
Cancer Research. 75:3923-3923
Malignant rhabdoid tumors are characterized by the loss of the SWI/SNF complex subunit SMARCB1. Atypical Teratoid Rhabdoid Tumor (ATRT) is a rare form of pediatric MRT that occurs in the CNS. Current treatment modalities for this tumor type continue
Autor:
Eiman Aleem, David W. Lee, Daniel H. Wai, Oliver B. Pepper, Ranjan Bista, David O. Azorsa, Robert J. Arceci
Publikováno v:
Cancer Research. 74:3982-3982
Background Despite toxic treatments, acute myeloid leukemia (AML) continues to have an overall poor prognosis of about 50% in children while significantly less in older adults. For patients with relapsed AML refractory to chemotherapy, there is littl
Autor:
David W. Lee, Nicole M. O'Connor, Ranjan Bista, Eiman Aleem, Sun-Mei Liu, Daniela S. Gerhard, Spyro Mousses, Robert J. Arceci, David O. Azorsa, Daniel H. Wai, Malcolm A. Smith, Tanja Davidsen, Michael F. Ochs, Oliver B. Pepper, Toni Farley, Soheil Meshinchi, Rhonda E. Ries, Michael Considine, Jason E. Farrar, Jaime Guidry-Auvil
Publikováno v:
Cancer Research. 74:5583-5583
Background Acute myeloid leukemia (AML) is a complex and heterogeneous disease leading to a wide range of response variability to conventional therapy, excessive treatment related toxicity, and an overall poor outcome. The NCI supported Therapeutical